A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

计划入组 54,000 人 · 首次发布于 2026 年 9 月 4 日

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

计划入组 324 人 · 首次发布于 2022 年 7 月 7 日

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

计划入组 776 人 · 首次发布于 2025 年 8 月 13 日

mRNA-based vaccine (influenza)

mRNA-based universal influenza vaccine (Tiba Biotech)

mRNA-based universal influenza vaccine (lipid nanoparticle, influenza)

Research Institute of Influenza

Russia

AIM VACCINE

China

EVIDENCE-BASED PRACTICE INSTITUTE, INC.

United States

Pfizer-BioNTech Launches Landmark Phase 3 Trial for mRNA-Based Influenza Vaccine

FDA Advisory Panel Reviews Moderna's mRNA-Based Influenza Vaccine mFlusiva, a First-of-Its-Kind Shot for Adults 50 and Older

Moderna Secures $590 Million HHS Award to Advance mRNA-Based Influenza Vaccine Development